Abstract
Objective: This study aimed to evaluate the effect of isolated vitamin D (VD) supplementation on the metabolic syndrome (MetS) risk profile in postmenopausal women.
Methods: In this double-blind, placebo-controlled trial, 160 postmenopausal women aged 50–65 years were randomized into two groups: VD group, supplementation with 1000 IU vitamin D3/day (n = 80); or placebo group (n = 80). The intervention time was 9 months, and the women were assessed at baseline and endpoint. Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glucose, and insulin, were measured. The plasma concentration of 25-hydroxyvitamin D (25(OH)D) was measured by high-performance liquid chromatography.
Results: After 9 months, there was a significant increase in the 25(OH)D levels for VD group (+45.4%, p < 0.001), and a decrease (−18.5%, p = 0.049) in the placebo group. In the VD group, a significant reduction was observed in triglycerides (−12.2%, p = 0.001), insulin (−13.7%, p = 0.008), and the homeostasis model assessment of insulin resistance (−17.9%, p = 0.007). In the placebo group, there was an increase in glucose (+6.2%, p = 0.009). Analysis of the risk adjusted for age, time since menopause, and body mass index showed that women supplemented with VD had a lower risk of MetS (odds ratio [OR] 0.42; 95% confidence interval [CI] 0.21–0.83), hypertriglyceridemia (OR 0.43; 95% CI 0.22–0.85), and hyperglycemia (OR 0.23; 95% CI 0.10–0.52) compared to the placebo group (p < 0.05).
Conclusions: In postmenopausal women with VD deficiency, isolated supplementation with 1000 IU vitamin D3 for 9 months was associated with a reduction in the MetS risk profile. Women undergoing VD supplementation had a lower risk of MetS, hypertriglyceridemia, and hyperglycemia.
Trial registration: Brazilian Clinical Trials Registry identifier: RBR-4MHS32.
摘要
目的: 本研究旨在评价单独补充维生素D(VD)对绝经后妇女代谢综合征(METS)风险的影响。
方法: 在这项双盲、安慰剂对照试验中, 160名年龄在50-65岁的绝经后妇女被随机分为两组:VD组, 每天补充1000IU维生素D3(n=80);或安慰剂组(n¼80)。干预时间为9个月, 并在基线和终点对妇女进行评估。收集临床和人体测量数据。测定生化参数, 包括总胆固醇、高密度脂蛋白、低密度脂蛋白、甘油三酯、葡萄糖和胰岛素。采用高效液相色谱法测定血浆25-羟基维生素D(25(OH)D)浓度。or
结果: 9个月后, VD组的25(OH)D水平显著增加(+45.4%, p<0.001), 而安慰剂组的25(OH)D水平下降(-18.5%, p=0.049)。在VD组中, 观察到甘油三酯(-12.2%, p=0.001)、胰岛素(-13.7%, p=0.008)和胰岛素抵抗的稳态模型评估(-17.9%, p=0.007)显著降低。在安慰剂组中, 血糖有升高(+6.2%, p=0.009)。对年龄、绝经时间和体重指数进行调整后的风险分析表明, 与安慰剂组相比, 服用VD的女性患MetS (比值比[OR]0.42;95%可信区间[CI]0.21-0.83)、高甘油三酯血症(OR 0.43;95%CI 0.22-0.85)和高血糖(OR 0.23;95%CI 0.10-0.52)的风险较低(p<0.05)。
结论: 在有VD缺乏的绝经后妇女中, 单独补充1000IU维生素D3 9个月与MetS风险降低相关。接受VD补充的妇女患MetS、高甘油三酯血症和高血糖的风险较低。
Potential conflict of interest
No potential conflict of interest was reported by the authors.